Chimeric hBPI23-Fcγ protein shows bactericidal activity against drug-resistant Gram-negative bacteria and protects mice from lethal challenge
Archives of Microbiology · 2025
DOI: 10.1007/s00203-025-04306-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Microbiology, 2025. Verfasst von Tianxiao Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Antimicrobial Cationic Peptides, Blood Proteins, Recombinant Fusion Proteins. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Medical Innovation Capacity Enhancement Special Program of Capital Medical University.
Abstract (Originalsprache)
The antimicrobial peptides, such as host immune system-derived human bactericidal/permeability-increasing protein (hBPI), are the potential drugs for antibiotic-resistant Gram-negative bacterial infection. However, whether the purified chimeric hBPI23-Fcγ protein has bactericidal activity against drug-resistant Gram-negative bacteria (GNB) and the relevant mechanisms have not been fully elucidated. In this study, the chimeric hBPI23-Fcγ protein, which consisting of the functional N terminus of BPI and Fcγ1, were expressed and purified in a lab-scale. The chimeric hBPI23-Fcγ protein showed longer half-life up to 148.2 min in vivo. The hBPI23-Fcγ protein also showed significant bactericidal activity against standard and clinically isolated drug-resistant Acinetobacter baumannii (A. baumannii) and Escherichia coli (E. coli). In addition, the hBPI23-Fcγ protein markedly decreased biofilm formation, neutralized bacterial lipopolysaccharides (endotoxin) and enhanced the opsonization of phagocytes, as well as significantly improved the survival rate of minimal lethal dose (MLD) of drug-resistant E. coli -infected mice. These results indicate that the BPI23-Fcγ protein protected mice from drug-resistant GNB infection not only by direct bactericidal effect, but also by promoting opsonophagocytosis of macrophages. In conclusion, the chimeric BPI23-Fcγ protein may be as a promising candidate of non-antibiotic biological agent for drug-resistant GNB infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.
- Beijing Anjun Genetech Co., LTD., Beijing, China.
- Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.
- HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
- Department of Respiratory Medicine, The First Hospital Affiliated to Army Medical University (Third Military Medical University), Chongqing, China.
- Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. kongql@ccmu.edu.cn.
Förderung
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
- Medical Innovation Capacity Enhancement Special Program of Capital Medical University
Zitieren
APA
Ma, T., Wang, Y., Huang, C., Zhang, X., An, Y., Zhang, Q., Kong, Q., & Cao, B. (2025). Chimeric hBPI23-Fcγ protein shows bactericidal activity against drug-resistant Gram-negative bacteria and protects mice from lethal challenge. Archives of Microbiology. https://doi.org/10.1007/s00203-025-04306-2
Vancouver
Ma T, Wang Y, Huang C, Zhang X, An Y, Zhang Q, et al. Chimeric hBPI23-Fcγ protein shows bactericidal activity against drug-resistant Gram-negative bacteria and protects mice from lethal challenge. Archives of Microbiology. 2025. doi:10.1007/s00203-025-04306-2
BibTeX
@article{Ma2025,
author = {Ma, Tianxiao and Wang, Yang and Huang, Chaoben and Zhang, Xulong and An, Yunqing and Zhang, Qi and Kong, Qingli and Cao, Bin},
title = {Chimeric hBPI23-Fcγ protein shows bactericidal activity against drug-resistant Gram-negative bacteria and protects mice from lethal challenge},
journal = {Archives of Microbiology},
year = {2025},
doi = {10.1007/s00203-025-04306-2}
}
EUVIMED